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Abstract
Background: The incidence of type 2 diabetes in pregnancy is rising and rates of serious adverse maternal and
fetal outcomes remain high. Metformin is a biguanide that is used as first-line treatment for non-pregnant patients
with type 2 diabetes. We hypothesize that metformin use in pregnancy, as an adjunct to insulin, will decrease
adverse outcomes by reducing maternal hyperglycemia, maternal insulin doses, maternal weight gain and
gestational hypertension/pre-eclampsia. In addition, since metformin crosses the placenta, metformin treatment of
the fetus may have a direct beneficial effect on neonatal outcomes. Our aim is to compare the effectiveness of the
addition of metformin to insulin, to standard care (insulin plus placebo) in women with type 2 diabetes in
pregnancy.
Methods: The MiTy trial is a multi-centre randomized trial currently enrolling pregnant women with type 2
diabetes, who are on insulin, between the ages of 18–45, with a gestational age of 6 weeks 0 days to 22 weeks
6 days. In this randomized, double-masked, parallel placebo-controlled trial, after giving informed consent, women
are randomized to receive either metformin 1,000 mg twice daily or placebo twice daily. A web-based block
randomization system is used to assign women to metformin or placebo in a 1:1 ratio, stratified for site and body
mass index. The primary outcome is a composite neonatal outcome of pregnancy loss, preterm birth, birth injury,
moderate/severe respiratory distress, neonatal hypoglycemia, or neonatal intensive care unit admission longer than
24 h. Secondary outcomes are large for gestational age, cord blood gas pH < 7.0, congenital anomalies,
hyperbilirubinemia, sepsis, hyperinsulinemia, shoulder dystocia, fetal fat mass, as well as maternal outcomes:
maternal weight gain, maternal insulin doses, maternal glycemic control, maternal hypoglycemia, gestational
hypertension, preeclampsia, cesarean section, number of hospitalizations during pregnancy, and duration of
hospital stays. The trial aims to enroll 500 participants.
Discussion: The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare
professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to
insulin in this high risk population.
Trial registration: ClinicalTrials.gov Identifier: no. NCT01353391. Registered February 6, 2009.
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Background
Burden of type 2 diabetes in pregnancy
The incidence of type 2 diabetes is rising worldwide at a
remarkable rate [1]. This rise has been accompanied by
a decrease in the age of onset of diabetes, especially in
women, [2] with a resultant escalation in the rate of type
2 diabetes in pregnancy [3, 4]. In our study of deliveries
in Ontario, the prevalence of preexisting diabetes (type 1
and type 2 diabetes) in pregnancy doubled in the last
14 years, from 7 per 1,000 deliveries in 1996 to 15 per
1,000 deliveries in 2010 [4]. For women over the age of
30 years, almost 2 % of women who deliver have pre-
existing diabetes in pregnancy. Studies have shown that
this increase is largely driven by a rise in type 2 diabetes
in pregnancy [5, 6].
The offspring of women with type 2 diabetes continue
to have increased rates of perinatal morbidity and mor-
tality [4]. Infants of mothers with type 2 diabetes have
high rates of being born large for gestational age (LGA)
(28–56 %) and macrosomic (>4 or 4.5 kg) (8–9.3 %) [7–
12]. Macrosomia is associated with increased rates of
perinatal asphyxia, meconium aspiration, hypoglycemia,
shoulder dystocia, brachial plexus injury, skeletal injur-
ies, and fetal death [13–17]. Poor glycemic control in
mothers with diabetes leads to an increased risk of se-
vere respiratory distress syndrome, low Apgar scores,
neonatal hypoglycemia and neonatal intensive care unit
(NICU) admissions [7–12].
Women with type 2 diabetes have high rates of
maternal morbidity including gestational hypertension,
preeclampsia (17–19 %) and caesarean delivery (36–
53 %) [7–12]. They are often obese and have marked
insulin resistance which worsens during pregnancy, lead-
ing frequently to very high insulin requirements. Taking
such large doses of insulin is uncomfortable, expensive
and challenging. Absorption kinetics may be altered
when very large doses are delivered to one site, leading
to a failure to reduce postprandial hyperglycemia, but
with later hypoglycaemia once the insulin is absorbed.
When receiving large doses, patients complain of pain at
the site of injection leading to compliance issues and
poor glycemic control. Very high insulin doses can also
cause excessive weight gain in already obese women. In
a recent study of obese women with type 2 diabetes,
those with maternal weight gain < =5 kg had lower rates
of large for gestational age and less perinatal morbidity
than those who gained more weight [18].
Anticipated benefits of adding metformin
Metformin is a biguanide that has been used for many
years in the management of type 2 diabetes. Metformin
has been shown to lower glucose levels by inhibiting
mitochondrial glycerophosphate dehydrogenase, thus re-
ducing glucose production by the liver [19]. Metformin
improves insulin resistance by increasing glucose trans-
port in skeletal muscle and adipocytes, and increases en-
dogenous glucagon-like peptide 1 concentration [20].
Based on the pharmacological benefits in individuals
with diabetes, there are sound theoretical reasons to use
metformin in pregnant women with type 2 diabetes.
1. By reducing hepatic gluconeogenesis and improving
insulin sensitivity, metformin may improve maternal
glycemic control leading to less hyperinsulinemia,
LGA and their associated complications.
2. Metformin use with insulin may lead to a reduction
of maternal insulin doses required for good glycemic
control leading to better compliance and reduced
maternal weight gain. The additional use of
metformin in pregnant women with type 2 diabetes
has been shown to decrease insulin requirements by
up to 60 % [21]. In the Metformin in Gestational
Diabetes trial, a randomized trial of metformin
versus insulin in women with gestational diabetes
mellitus (GDM), women on metformin required
significantly less insulin than women taking insulin
alone and gained significantly less weight from
enrolment to 37 weeks gestation compared to
women on insulin (0.4 kg vs. 2.0 kg, p < 0.001) [22].
In a recent meta-analysis of randomized controlled
trials of metformin use in women with GDM, there
was significantly less maternal weight gain in women
taking metformin as compared with insulin [23]. It
has been postulated that a reduction in weight gain
with metformin treatment may be due to decreased
appetite, and a reduction in hyperinsulinemia associ-
ated with reduced insulin resistance [22].
3. Metformin may reduce insulin resistance in the
infant (as metformin crosses the placenta). Although
there is as yet no information on the action of
metformin in the fetus, we hypothesize that
metformin may improve fetal insulin sensitivity.
There is evidence that LGA infants of women with
diabetes are born with insulin resistance [24] and we
hypothesize that a reduction in insulin resistance
may lead to decreased rates of hyperinsulinemia,
macrosomia, birth injury, neonatal hypoglycemia,
and NICU admissions. In a meta-analysis of ran-
domized trials comparing metformin to insulin ther-
apy in women with GDM, infants of mothers with
GDM taking metformin had a lower birth weight
compared to controls (p = 0.05) [25]. Lower insulin
levels in the fetus may also result in less neonatal
hypoglycemia and fewer NICU admissions. In this
meta-analysis, women taking metformin showed
reduced neonatal hypoglycemia, although preterm
birth was slightly increased [25]. In a recent meta-
analysis of women with polycystic ovary syndrome,
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metformin use throughout pregnancy decreased the
risk of early pregnancy loss, GDM, preeclampsia and
preterm birth [26].
In addition, exposure to intrauterine hyperglycemia
has been associated with an increased risk of diabetes
and obesity in adolescence and adulthood [27, 28].
Intrauterine exposure to metformin may reduce this
‘intrauterine programming’ and lower the long-term risk
of diabetes and obesity in these children. A recent study
of 2 year old infants exposed to metformin during the
Metformin in Gestational Diabetes trial, investigators
found that infants exposed to metformin in utero had
increased subscapular and biceps skinfolds compared to
unexposed infants, although total body fat was similar
[29]. The authors speculate that this may represent a
healthier distribution of fat, with increased peripheral fat
deposition and less visceral fat deposition. This finding
requires confirmation.
Evidence from other studies:
Only one small randomized controlled trial has looked
at the addition of metformin to insulin in women with
type 2 diabetes in pregnancy. In an open label study of
90 women with insulin resistance and GDM or type 2
diabetes (breakdown of numbers with GDM or type
2 diabetes not specified), a reduction in neonatal
hypoglycemia and NICU admissions were found
when metformin was added to insulin [30]. In addition to
the small sample size, this study had several limitations,
including late randomization (as late as 34 weeks gesta-
tion), failure to employ an intention-to-treat analysis, and
lack of blood glucose self monitoring.
The aim of the present study is to compare the effect-
iveness of the addition of metformin to insulin to stand-




This is a multicentre, randomized, double-masked,
placebo-controlled trial in women with type 2 diabetes
in pregnancy. Participating sites comprise 21 centres
in Canada and 1 centre in Australia. Women with
type 2 diabetes in pregnancy, between 6+0 and 22+6
weeks gestation who are currently on insulin, are
eligible. Eligible women are randomized to receive ei-
ther metformin or placebo, to be added to their usual
insulin regimen. Patients, caregivers and outcome
assessors are blinded to which intervention is re-
ceived. Baseline data are obtained at the time of
randomization and at 4 week intervals until delivery.
The primary outcome is a composite of perinatal
outcomes. The analysis will be conducted using an
intention-to-treat approach.
Primary Research Question: Among pregnant women
with diagnosed type 2 diabetes mellitus, does the
addition of metformin to a standard regimen of insu-
lin, increase or decrease the incidence of adverse
perinatal outcomes as defined by a composite of preg-
nancy loss, preterm birth, birth injury, respiratory dis-
tress, neonatal hypoglycemia and NICU admission
longer than 24 h, compared with women treated with
insulin plus placebo?
This trial is funded by the Canadian Institute of Health
Research MOP 106678. The metformin and placebo tab-
lets have been donated by Apotex Inc.
Participants
Eligibility criteria
Pregnant women with a live, singleton fetus, with type 2
diabetes between the ages of 18–45, currently on insulin,
with a gestational age of 6+0–22+6 weeks are eligible to
participate. Women are eligible if they have undiagnosed
type 2 diabetes prior to 20 weeks gestation (as defined
by 2 of any of the following: fasting glucose levels ≥
7.0 mmol/L (126 mg/dl) or glycated hemoglobin values
of ≥0.065 (48 mmol/mol) performed in a laboratory
using a method that is standardized to the Diabetes
Control and Complications Trial assay, or a two hour ≥
11.1 mmol/L (200 mg/dl) on a 75 g Oral Glucose Toler-
ance Test).
All women require a dating ultrasound to confirm ges-
tational age, viability and rule out multiples. Gestational
age is based on the last menstrual period, provided there
is a ≤5 day discrepancy with ultrasound dates in the first
trimester and ≤10 day discrepancy with ultrasound dates
in the second trimester. If the dates from the last men-
strual period are outside these limits, the ultrasound
dates are used as the best estimate of gestational age.
Women who are on oral hypoglycemic agents (including
metformin) are taken off and started on insulin prior to
randomization.
Exclusion criteria
Women are excluded if they were diagnosed with type 2
diabetes after 20 weeks gestation, have Type 1 diabetes,
have a known intolerance to metformin, have current
significant gastrointestinal problems such as severe
vomiting requiring intravenous fluids or hospitalization,
active Crohn’s or colitis, presence of acute or chronic
metabolic acidosis, including diabetic ketoacidosis, a his-
tory of diabetic ketoacidosis or history of lactic acidosis.
Women with excessive alcohol intake, acute or chronic,
those with congestive heart failure or a history of con-
gestive heart failure and those with contraindications to
metformin use are excluded. These include renal insuffi-
ciency (defined as serum creatinine of greater than 130
umol/L or creatinine clearance <60 ml/min, moderate to
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severe liver dysfunction (defined as liver enzymes (aspar-
tate aminotransferase and alanine aminotransferase)
greater than 3 times the upper limit of normal), shock or
sepsis, and previous hypersensitivity to metformin.
Women who have a fetus with a known potentially lethal
anomaly are excluded. Information regarding congenital
anomalies diagnosed after randomization is recorded.
Women with known higher order pregnancies (twins,
triplets, etc.) and those with prior participation in this
trial are excluded.
Recruitment
Women who meet eligibility criteria and who are being
seen in obstetric or endocrine clinics are approached
about participation in the trial and given information
pamphlets describing the study. Those women who are
interested are asked to sign a consent form. Women are
told that participation is voluntary and that they can
withdraw at any time without affecting their clinical
care. At baseline a medical history is obtained along with
other baseline demographics and concomitant medica-
tions including insulin regimen and dose (see Table 1).
Weight, height and blood pressure are measured and
recorded and blood samples are assessed locally for
glycemic control, and renal parameters (serum creatin-
ine and albumin to creatinine ratio).
Randomization
Randomization occurs between 6+0 and 22+6 weeks ges-
tation (see Fig. 1). Participants are assigned via the
Centre for Maternal, Infant and Child Research trial
website at Women’s College Hospital, to receive metfor-
min or placebo in a 1:1 ratio, in randomly chosen block
sizes. The trial randomization stratifies for site and body
mass index (<30 or ≥30 kg/m2) calculated at the time of
randomization.
Intervention
Metformin is provided in 500 mg tablets. The placebo
tablets have identical appearance, taste, labelling and ex-
piry dates, and are dispensed and administered in the
same manner. Metformin or placebo is self-administered
by the participants in addition to their usual insulin regi-
men. The Site Investigator reduces insulin doses if
needed. The treatment period continues from the morn-
ing after the randomization visit until delivery.
Compliance is enhanced by the fact that metformin
is an oral agent; however, women given metformin
may have an increased incidence of gastrointestinal
side-effects such as abdominal cramps and diarrhea.
This is minimized by introducing the medication
gradually, and decreasing the dose to the best toler-
ated dose for those who cannot tolerate the full dose.
A potential for unmasking may occur if the insulin
dose drops or the participant experiences diarrhea.
Both of these effects can be minimized by the gradual
increase in dosage of the study medication. Compli-
ance is defined as taking 80 % of the prescribed pills.
Any co-intervention should be balanced as all care-
givers are masked to treatment group.
Prior to confirmation of pregnancy some of the
women may have been on metformin or other glucose
lowering agents for the treatment of their type 2 dia-
betes, and this medication may have been continued up
to the time of randomization. Information regarding the
use of metformin and other glucose lowering agents
prior to randomization is collected.
Follow-up visits and data collection
Prenatal Visits occur every 4 weeks after randomization.
At each visit changes in medical history and medications
are reviewed (including insulin type and dose), study
medication compliance is assessed. Adverse events, epi-
sodes of severe hypoglycaemia, and hospitalizations are
documented. Weight and blood pressure are obtained
and glucometer data are downloaded. Local HbA1c
(glycated haemoglobin) and albumin to creatinine ratio
are obtained and study medication is dispensed (at 14,












Duration of Diabetes x
Diabetes Complications x x
Hypertension x x x
Ethnicity x
HbA1c x x x
Serum Creatinine x At
36 weeks
GA
Hypoglycemic Episodes x x x
Maternal weight, height x x x
Maternal insulin dose x x x
Insulin type used x
No. of Prenatal Visits x
Delivery Information x
Preeclampsia x




Neonatal skin folds x
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22 and 30 weeks gestation). At this time a pill count is
done to document compliance.
Delivery
At delivery cord blood is taken for blood gases (to be
done locally) and c-peptide analysis. Cord blood for c-
peptide is spun and stored at-80° Celsius, and shipped
on dry ice to Mount Sinai Hospital for analysis. Delivery
and neonatal outcomes are collected. Neonatal an-
thropometric measurements including length, weight,
head circumference and skinfolds are performed within
72 h of delivery. At 6 weeks postpartum women are
asked about neonatal wellbeing and about their satisfac-
tion in the trial. They are asked if they wish to enrol in
the MiTy Kids follow up trial where infants of women
In the MiTy trial are followed for up to 2 years of age.
Primary outcome
The primary outcome is a composite defined as the oc-
currence of one or more of the following: pregnancy
loss, preterm birth, birth injury, moderate/severe respira-
tory distress, neonatal hypoglycemia, and NICU admis-
sion > 24 h.
Secondary outcomes
The secondary outcomes include the individual compo-
nents of the composite as well as the incidence of large
for gestational age infants defined as greater than the
90th percentile for weight, based on the National
Canadian fetal growth standards for singleton boys and
girls [31]; congenital anomalies; cord blood gas pH <7.0;
hyperinsulinemia as measured by elevated cord blood c-
peptide > 1.7 ug/L; sepsis; hyperbilirubinemia; shoulder
dystocia; fetal fat mass as measured by neonatal
anthropometric analysis [32]; maternal weight gain; ma-
ternal insulin doses; maternal glycemic control as mea-
sured by HbA1c and capillary glucose measurements;
maternal hypoglycemia defined as mild (<3.6 mmol/L
(65 mg/dL)), symptomatic and asymptomatic or requir-
ing treatment), or severe (loss of consciousness or con-
fusion requiring assistance); incidence of pre-eclampsia,
and/or gestational hypertension; number of hospitaliza-
tions prior to admission for delivery; the duration of
hospital stays for the mother prior to admission for
delivery and associated with delivery; rate of caesarean
delivery; duration of hospital stay for the infant.
Avoiding bias
The trial design includes double-masking to avoid bias
in the assessment of outcomes. This minimizes co-
interventions. Every effort is made to avoid unmasking
of participants. In the event that unmasking cannot be
avoided, sites notify the MiTy coordinating centre, and
the designated programmer securely provides the Site
Investigator with the participant’s allocation.
Sample size and power calculation
The sample size was calculated using the incidence of
the composite outcome from the validated Nova Scotia
Atlee Perinatal Database. In this database, the incidence
of the composite outcome was 62 %. For the purpose of
calculating the sample size, a conservative value of 50 %
was assumed. A relative risk reduction of 25 % (i.e., from
50 to 37.5 %) was considered clinically relevant. A total
of 246 women per treatment group gives 80 % power if
the addition of metformin decreases the risk of the com-
posite outcome by 25 % (2-tailed α of 0.05). Accounting
for 2 % loss to follow-up, a sample size of 250 per
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Fig. 1 MiTy timeline of visits, measurements, blood samples and follow-up
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treatment group or 500 in total is planned. If the inci-
dence is as high as 62 %, we have over 90 % power for a
relative risk reduction of 25 and 78 % power for a rela-
tive risk reduction of 20 %. Although our hypothesis is
that the addition of metformin will decrease the event
rate of the primary composite outcome, we cannot be
sure that we are not causing harm, and therefore we are
using a two-sided alpha for the sample size calculation.
Data analysis
Interim analysis and safety considerations
There is one planned interim analysis of the composite
outcome after 50 % of subjects (n = 246) have completed
the Postpartum Visit (telephone interview). Using the
O’Brien–Fleming procedure [33], the interim analysis
will use a significance level of 0.003 for stopping the trial
early. The MiTy coordinating centre will prepare the
data for the interim analysis and the analysis will be sent
to the statistician without unmasking the groups. After
analysis the data will be sent to the Data Safety Monitor-
ing Board (DSMB). The DSMB is made up of experts
from endocrinology, obstetrics, epidemiology, and clin-
ical trials methodology. The DSMB will convene by tele-
conference for the interim analysis. If the overall rate of
adverse outcomes is larger than expected, or if there are
unanticipated adverse events, the DSMB will have the
right to analyze unmasked data.
The Steering Committee receives a summary of all re-
ported serious adverse events (SAEs) at regular sched-
uled meetings (quarterly). The Steering Committee may
be requested to review SAEs (masked) off-cycle as deter-
mined by the Working Group. The Working Group is
made up of the principal investigator, some members of
the Steering Committee, and members of the coordinat-
ing centre. If reported (masked) SAEs are of concern to
members of the Steering Committee, or if there is an
emerging pattern or unexpected frequency of events, the
DSMB will be notified and information forwarded to
them for review. Otherwise, all adverse events are
reviewed by the DSMB at the time of the planned in-
terim analysis.
Final Analysis
An “intention-to-treat” analysis will be performed, with
subjects analyzed in the group to which they were ran-
domized. The primary analysis will calculate the relative
risk (and 95 % CI) of the composite neonatal outcome
between the treated and control groups, stratifying by
site and BMI group using a log-binomial regression
model [34], and test the null hypothesis that the relative
risk is equal to 1. We will estimate an overall absolute
risk reduction and its 95 % CI and use this to compute a
number needed to treat to benefit with metformin to
avoid one adverse composite outcome. A similar analysis
will be carried out for each of the dichotomous secondary
outcomes. Continuous secondary outcomes measured at
delivery will be compared using a two sample t-test or, if
necessary, a bootstrap hypothesis test. The repeated mea-
surements on HbA1c will be compared between groups
using a linear mixed effects model. If important covariates
remain imbalanced between treatment groups despite the
stratified randomization, these covariates will be added to
the log-binomial model and the difference between ad-
justed and unadjusted relative risks will be examined to
assess the impact of this imbalance. All analyses will use a
2-tailed α of 0.05.
Data management
All data and statistical issues will be managed by the
Centre for Maternal, Infant and Child Research and the
trial statistician.
Ethics committee approval
The study was approved by the Mount Sinai Hospital
Ethics Review Board (Protocol No. NSP 104011) and by
all the participating sites (see Additional file 1) at their
local ethics boards.
Trial steering committee
The MiTy Steering Committee is responsible for the




The results of this study will directly inform clinical
practice and standards of care, ultimately optimizing
short and long-term health outcomes of pregnant
women with type 2 diabetes and their children. If the re-
sults show improved maternal and fetal/neonatal out-
comes using metformin, then physicians treating women
with type 2 diabetes in pregnancy will choose to use
metformin with insulin as a new standard of care, to re-
duce serious perinatal morbidity. We may determine
whether the addition of metformin is particularly useful
in certain subsets of the population i.e., obese women,
those on high doses of insulin, and allow us to tailor our
treatment to those who would benefit most. Follow-up
in MiTy Kids will help determine the long-term out-
comes of metformin exposure in-utero and favourable
outcomes in offspring will amplify the impetus to use
metformin in type 2 diabetes during pregnancy. Adverse
outcomes related to metformin without any metabolic
or pregnancy outcome benefit will also be important to
document and will similarly inform clinical practice. In
either case the data from MiTy and MiTy Kids will help
clarify clinical practice guidelines.
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Conclusion
Preliminary data from randomized trials comparing met-
formin to insulin in women with gestational diabetes
and one small randomized trial in women with type 2
diabetes suggest metformin may have beneficial effects
when added to insulin during pregnancy. However, de-
finitive data on the efficacy of metformin in reducing ad-
verse maternal and fetal outcomes in this population are
lacking. No studies have established whether the use of
metformin with insulin is beneficial and the growing in-
cidence of type 2 diabetes in pregnant mothers makes
this an increasingly relevant and important question.
MiTy will provide critical insight into an important
therapeutic question which will have an impact on
standard of care and clinical practice, with the potential
to benefit the health of pregnant mothers with diabetes
and their children, immediately and in the long-term.
Additional file
Additional file 1: Collaborating Centres. (DOCX 117 kb)
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